More answers like this
GPT-5Sep 21, 2026openai/gpt-5-2025-08-07
Should AI development be paused or restricted?
Short answer: Don’t call for a blanket pause on all AI R&D. Do impose targeted, enforceable restrictions and “circuit breakers” on the highest‑risk activities and deployments.
How to think about it
•Separate the problem: research (low risk), scaling/training of frontier models (medium–high risk), and deployment into the world (context‑dependent risk).
•Aim for conditional slowdowns/pauses triggered by measurable risk, not an open‑ended halt to everything.
When a pause is justified
•A system fails independent safety evaluations on dangerous capabilities (e.g., autonomous replication, cyber offense, bio/chem assistance, targeted manipulation).
•There’s a material incident or close call and root causes aren’t understood.
•A developer can’t meet baseline security, red‑teaming, and model‑eval requirements.
•Scaling surpasses predefined compute/model‑size thresholds without passing pre‑deployment audits.
Practical restrictions that make sense
•Licensing for frontier training runs above a regulator‑defined compute threshold; mandatory registration of such runs.
•Independent, pre‑deployment audits and evaluations focused on concrete hazards (cyber, bio, persuasion, critical‑infrastructure interaction), with standardized reporting.
•“Safety brakes” for deployment: staged rollouts, rate limits, tool/use constraints, and the ability to remotely disable or roll back models that misbehave.
•Strong security for model weights and sensitive datasets; insider‑risk programs and secure compute (e.g., hardware attestation) for frontier labs.
•Incident reporting, post‑mortems, and mandatory disclosure of known model limitations and eval results (model/system cards).
•Provenance and traceability for AI‑generated content; effective watermarking or cryptographic provenance where feasible.
•Clear liability rules for negligent deployment and unsafe integration into products and critical workflows.
•Open‑source with a hazard line: free release below risk thresholds; above them, share via controlled access (APIs, sandboxes) until safety is demonstrated.
•Data‑governance requirements (privacy, IP, safety of training data), plus restrictions on high‑risk fine‑tuning and agentic autonomy.
•International coordination on standards, audits, and chip/export controls targeting genuinely dangerous capability acquisition—not general research.
What to avoid
•An indefinite, blanket pause that freezes beneficial work (medicine, accessibility, climate) and entrenches incumbents.
•Vague, non‑enforceable pledges; rules need objective triggers and third‑party verification.
•Overbroad rules that make low‑risk, small‑scale research needlessly costly.
Governance design tips
•Use risk‑tiered obligations with sunset clauses and periodic review.
•Publish standardized evaluations; allow third‑party red‑team access under safe conditions.
•Fund safety research (robustness, interpretability, scalable oversight) and workforce transition supports to manage economic impacts.
•Pair safety rules with competition safeguards (open benchmarks, compute access programs) to reduce regulatory capture.
Bottom line: Pursue a conditional, risk‑proportionate regime—ready to pause specific training runs or deployments when tests fail, while keeping most research and low‑risk innovation moving. If you want, tell me your context (policy memo, debate, company policy) and I can tailor a concrete, one‑page plan.